Analysis of serum metabolic profile by ultra-performance liquid chromatography-mass spectrometry for biomarkers discovery: Application in a pilot study to discriminate patients with tuberculosis

Chinese Medical Journal

Volumn 128, Issue 2, 2015, Pages 159-168

  Feng, Shuang ^a   Du, Yan Qing ^a   Zhang, Li ^a   Zhang, Lei ^b   Feng, Ran Ran ^a   Liu, Shu Ye ^b  

^a Haihe Hospital   (China)

^b the Third Center Hospital   (China)

Author keywords

Metabolites; Orthogonal partial least squares discriminant analysis; Serum; Tuberculosis; Ultra performance liquid chromatography mass spectrometry

Indexed keywords

AMINO ACID; BEHENIC ACID; BIOLOGICAL MARKER; FATTY ACID; GLUTAMIC ACID; KYNURENINE; LIPID; LYSOPHOSPHATIDYLCHOLINE; PHOSPHOLIPID; PHYTANIC ACID; PRESQUALENE DIPHOSPHATE; SQUALENE DERIVATIVE; TERPENOID DERIVATIVE; THREONINYL GAMMA GLUTAMATE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD EXAMINATION; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ELECTROSPRAY; FEMALE; HUMAN; INSTRUMENT VALIDATION; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; METABOLITE; MIDDLE AGED; PILOT STUDY; RECEIVER OPERATING CHARACTERISTIC; SIGNAL NOISE RATIO; TUBERCULOSIS; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; UPREGULATION; AGED; BLOOD; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PROCEDURES;

ADULT; AGED; BIOLOGICAL MARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; TUBERCULOSIS;

EID: 84928263613     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.4103/0366-6999.149188     Document Type: Article

References (46)

1. Nicholson JK, Lindon JC, Holmes E. ‘Metabonomics’: Understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999;29:1181-1189.
2. Illig T, Gieger C, Zhai G, Römisch-Margl W, Wang-Sattler R, Prehn C, et al. A genome-wide perspective of genetic variation in human metabolism. Nat Genet 2010;42:137-141.
3. Kaddurah-Daouk R, Kristal BS, Weinshilboum RM. Metabolomics: A global biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol 2008;48:653-683.
4. Han X, M Holtzman D, McKeel DW Jr, Kelley J, Morris JC. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer’s disease: Potential role in disease pathogenesis. J Neurochem 2002;82:809-818.
5. Bogdanov M, Matson WR, Wang L, Matson T, Saunders-Pullman R, Bressman SS, et al. Metabolomic profiling to develop blood biomarkers for Parkinson’s disease. Brain 2008;131:389-396.
6. Sabatine MS, Liu E, Morrow DA, Heller E, McCarroll R, Wiegand R, et al. Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation 2005;112:3868-3875.
7. Brindle JT, Nicholson JK, Schofield PM, Grainger DJ, Holmes E. Application of chemometrics to 1H NMR spectroscopic data to investigate a relationship between human serum metabolic profiles and hypertension. Analyst 2003;128:32-36.
8. Yang J, Xu G, Zheng Y, Kong H, Pang T, Lv S, et al. Diagnosis of liver cancer using HPLC-based metabonomics avoiding false-positive result from hepatitis and hepatocirrhosis diseases. J Chromatogr B Analyt Technol Biomed Life Sci 2004;813:59-65.
9. Wang C, Kong H, Guan Y, Yang J, Gu J, Yang S, et al. Plasma phospholipid metabolic profiling and biomarkers of type 2 diabetes mellitus based on high-performance liquid chromatography/ electrospray mass spectrometry and multivariate statistical analysis. Anal Chem 2005;77:4108-4116.
10. Yuan K, Kong H, Guan Y, Yang J, Xu G. A GC-based metabonomics investigation of type 2 diabetes by organic acids metabolic profile. J Chromatogr B Analyt Technol Biomed Life Sci 2007;850:236-240.
11. Salek RM, Maguire ML, Bentley E, Rubtsov DV, Hough T, Cheeseman M, et al. A metabolomic comparison of urinary changes in type 2 diabetes in mouse, rat, and human. Physiol Genomics 2007;29:99-108.
12. Suhre K, Wallaschofski H, Raffler J, Friedrich N, Haring R, Michael K, et al. A genome-wide association study of metabolic traits in human urine. Nat Genet 2011;43:565-569.
13. Laiakis EC, Morris GA, Fornace AJ, Howie SR. Metabolomic analysis in severe childhood pneumonia in the Gambia, West Africa: Findings from a pilot study. PLoS One 2010;5.
14. Wang Y, Utzinger J, Saric J, Li JV, Burckhardt J, Dirnhofer S, et al. Global metabolic responses of mice to Trypanosoma brucei brucei infection. Proc Natl Acad Sci U S A 2008;105:6127-6132.
15. Slupsky CM, Rankin KN, Fu H, Chang D, Rowe BH, Charles PG, et al. Pneumococcal pneumonia: Potential for diagnosis through a urinary metabolic profile. J Proteome Res 2009;8:5550-5558.
16. Lönnroth K, Castro KG, Chakaya JM, Chauhan LS, Floyd K, Glaziou P, et al. Tuberculosis control and elimination 2010-50: Cure, care, and social development. Lancet 2010;375:1814-1829.
17. de Carvalho LP, Darby CM, Rhee KY, Nathan C. Nitazoxanide disrupts membrane potential and intrabacterial pH homeostasis of Mycobacterium tuberculosis. ACS Med Chem Lett 2011;2:849-854.
18. Cheng J, Krausz KW, Li F, Ma X, Gonzalez FJ. CYP2E1-dependent elevation of serum cholesterol, triglycerides, and hepatic bile acids by isoniazid. Toxicol Appl Pharmacol 2013;266:245-253.
19. Halouska S, Fenton RJ, Barletta RG, Powers R. Predicting the in vivo mechanism of action for drug leads using NMR metabolomics. ACS Chem Biol 2012 20;7:166-171.
20. Bisson GP, Mehaffy C, Broeckling C, Prenni J, Rifat D, Lun DS, et al. Upregulation of the phthiocerol dimycocerosate biosynthetic pathway by rifampin-resistant, rpoB mutant Mycobacterium tuberculosis. J Bacteriol 2012;194:6441-6452.
21. Mahapatra S, Hess AM, Johnson JL, Eisenach KD, DeGroote MA, Gitta P, et al. A metabolic biosignature of early response to anti-tuberculosis treatment. BMC Infect Dis 2014;14:53.
22. Shin JH, Yang JY, Jeon BY, Yoon YJ, Cho SN, Kang YH, et al. (1) H NMR-based metabolomic profiling in mice infected with Mycobacterium tuberculosis. J Proteome Res 2011;10:2238-2247.
23. Somashekar BS, Amin AG, Rithner CD, Troudt J, Basaraba R, Izzo A, et al. Metabolic profiling of lung granuloma in Mycobacterium tuberculosis infected guinea pigs: ex vivo 1H magic angle spinning NMR studies. J Proteome Res 2011;10:4186-4195.
24. Weiner J III, Parida SK, Maertzdorf J, Black GF, Repsilber D, Telaar A, et al. Biomarkers of inflammation, immunosuppression and stress with active disease are revealed by metabolomic profiling of tuberculosis patients. PLoS One 2012;7:e40221.
25. Zhou A, Ni J, Xu Z, Wang Y, Lu S, Sha W, et al. Application of (1) h NMR spectroscopy-based metabolomics to sera of tuberculosis patients. J Proteome Res 2013 4;12:4642-4649.
26. Chai W, Liu Z. p38 mitogen-activated protein kinase mediates palmitate-induced apoptosis but not inhibitor of nuclear factor-kappaB degradation in human coronary artery endothelial cells. Endocrinology 2007;148:1622-1628.
27. McKinney JD, Höner zu Bentrup K, Munoz-Elias EJ, Miczak A, Chen B, Chan WT, et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 2000;406:735-738.
28. Sandoval-Montemayor NE, García A, Elizondo-Trevino E, Garza-Gonzalez E, Alvarez L, del Rayo Camacho-Corona M. Chemical composition of hexane extract of Citrus aurantifolia and anti-Mycobacterium tuberculosis activity of some of its constituents. Molecules 2012;17:11173-11184.
29. Johnston JB, Singh AA, Clary AA, Chen CK, Hayes PY, Chow S, et al. Substrate analog studies of the ω-regiospecificity of Mycobacterium tuberculosis cholesterol metabolizing cytochrome P450 enzymes CYP124A1, CYP125A1 and CYP142A1. Bioorg Med Chem 2012;20:4064-4081.
30. Dubnau E, Chan J, Mohan VP, Smith I. Responses of Mycobacterium tuberculosis to growth in the mouse lung. Infect Immun 2005;73:3754-3757.
31. Cater NB, Denke MA. Behenic acid is a cholesterol-raising saturated fatty acid in humans. Am J Clin Nutr 2001;73:41-44.
32. Malyankar UM. Tumor-associated antigens and biomarkers in cancer and immune therapy. Int Rev Immunol 2007;26:223-247.
33. Taylor GO, Bamgboye AE. Serum cholesterol and diseases in Nigerians. Am J Clin Nutr 1979;32:2540-2545.
34. Peteroy-Kelly M, Venketaraman V, Connell ND. Effects of Mycobacterium bovis BCG infection on regulation of L-arginine uptake and synthesis of reactive nitrogen intermediates in J774.1 murine macrophages. Infect Immun 2001;69:5823-5831.
35. Murphy RA, Bureyko TF, Mourtzakis M, Chu QS, Clandinin MT, Reiman T, et al. Aberrations in plasma phospholipid fatty acids in lung cancer patients. Lipids 2012;47:363-9.
36. Oestvang J, Anthonsen MW, Johansen B. LysoPC and PAF trigger arachidonic acid release by divergent signaling mechanisms in monocytes. J Lipids 2011;2011:532145.
37. Duan L, Gan H, Arm J, Remold HG. Cytosolic phospholipase A2 participates with TNF-alpha in the induction of apoptosis of human macrophages infected with Mycobacterium tuberculosis H37Ra. J Immunol 2001;166:7469-76.
38. Mehta D, Gupta S, Gaur SN, Gangal SV, Agrawal KP. Increased leukocyte phospholipase A2 activity and plasma lysophosphatidylcholine levels in asthma and rhinitis and their relationship to airway sensitivity to histamine. Am Rev Respir Dis 1990;142:157-61.
39. Fallah A, Pierre R, Abed E, Moreau R. Lysophosphatidylcholine-induced cytotoxicity in osteoblast-like MG-63 cells: Involvement of transient receptor potential vanilloid 2 (TRPV2) channels. Mol Membr Biol 2013;30:315-26.
40. Blumenthal A, Nagalingam G, Huch JH, Walker L, Guillemin GJ, Smythe GA, et al. M. tuberculosis induces potent activation of IDO-1, but this is not essential for the immunological control of infection. PLoS One 2012;7:e37314.
41. Song H, Park H, Kim YS, Kim KD, Lee HK, Cho DH, et al. L-kynurenine-induced apoptosis in human NK cells is mediated by reactive oxygen species. Int Immunopharmacol 2011;11:932-8.
42. Apalset EM, Gjesdal CG, Ueland PM, Midttun Ø, Ulvik A, Eide GE, et al. Interferon (IFN)-γ-mediated inflammation and the kynurenine pathway in relation to bone mineral density: The Hordaland Health Study. Clin Exp Immunol 2014;176:452-60.
43. Chuang SC, Fanidi A, Ueland PM, Relton C, Midttun O, Vollset SE, et al. Circulating biomarkers of tryptophan and the kynurenine pathway and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2014;23:461-8.
44. Molina-Salinas GM, Bórquez J, Said-Fernandez S, Loyola LA, Yam-Puc A, Becerril-Montes P, et al. Antituberculosis activity of alkylated mulinane diterpenoids. Fitoterapia 2010;81:219-22.
45. Koohang A, Bailey JL, Coates RM, Erickson HK, Owen D, Poulter CD. Enantioselective inhibition of squalene synthase by aziridine analogues of presqualene diphosphate. J Org Chem 2010 16;75:4769-77.
46. Bonnans C, Fukunaga K, Keledjian R, Petasis NA, Levy BD. Regulation of phosphatidylinositol 3-kinase by polyisoprenyl phosphates in neutrophil-mediated tissue injury. J Exp Med 2006;203:857-63.